Minimal Residual Disease Testing Market Size, Share & Trends Report

Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (NGS, PCR), Cancer Type (Hematological Malignancy), By End-use (Hospitals), By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-4-68040-016-3
  • Number of Pages: 130
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Market Segmentation

  • Minimal Residual Disease Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)
    • Flow Cytometry
    • Polymerase Chain Reaction (PCR)
    • Next Generation Sequencing (NGS)
    • Others
  • Minimal Residual Disease Testing Cancer Type Outlook (Revenue, USD Million, 2018 - 2030)
    • Haematological Malignancy
      • Leukaemia
      • Lymphoma
    • Solid Tumours
  • Minimal Residual Disease Testing Business Outlook (Revenue, USD Million, 2018 - 2030)
    • Hospitals and Speciality Clinics
    • Diagnostic Laboratories
    • Academic and Research Institutes
    • Others
  • Minimal Residual Disease Testing Market Regional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • North America Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
        • Flow Cytometry
        • Polymerase Chain Reaction (PCR)
        • Next Generation Screening (NGS)
        • Others
      • North America Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
        • Hematological Malignancy
          • Leukemia
          • Lymphoma
        • Solid Tumors
      • North America Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
        • Hospitals and Specialty Clinics
        • Diagnostic Laboratories
        • Academic and Research Institutes
        • Others
      • U.S.
        • U.S. Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • U.S. Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • U.S. Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Canada
        • Canada Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Canada Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Canada Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
    • Europe
      • Europe Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
        • Flow Cytometry
        • Polymerase Chain Reaction (PCR)
        • Next Generation Screening (NGS)
        • Others
      • Europe Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
        • Hematological Malignancy
          • Leukemia
          • Lymphoma
        • Solid Tumors
      • Europe Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
        • Hospitals and Specialty Clinics
        • Diagnostic Laboratories
        • Academic and Research Institutes
        • Others
      • UK
        • UK Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • UK Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • UK Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Germany
        • Germany Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Germany Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Germany Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • France
        • France Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • France Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • France Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Italy
        • Italy Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Italy Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Italy Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Spain
        • Spain Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Spain Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Spain Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Denmark
        • Denmark Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Denmark Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Denmark Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Sweden
        • Sweden Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Sweden Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Sweden Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Norway
        • Norway Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Norway Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Norway Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
    • Asia Pacific
      • Asia Pacific Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
        • Flow Cytometry
        • Polymerase Chain Reaction (PCR)
        • Next Generation Screening (NGS)
        • Others
      • Asia Pacific Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
        • Hematological Malignancy
          • Leukemia
          • Lymphoma
        • Solid Tumors
      • Asia Pacific Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
        • Hospitals and Specialty Clinics
        • Diagnostic Laboratories
        • Academic and Research Institutes
        • Others
      • Japan
        • Japan Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Japan Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Japan Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • China
        • China Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • China Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • China Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • India
        • India Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • India Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • India Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Australia
        • Australia Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Australia Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Australia Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Thailand
        • Thailand Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Thailand Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Thailand Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • South Korea
        • South Korea Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • South Korea Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • South Korea Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
    • Latin America
      • Latin America Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
        • Flow Cytometry
        • Polymerase Chain Reaction (PCR)
        • Next Generation Screening (NGS)
        • Others
      • Latin America Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
        • Hematological Malignancy
          • Leukemia
          • Lymphoma
        • Solid Tumors
      • Latin America Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
        • Hospitals and Specialty Clinics
        • Diagnostic Laboratories
        • Academic and Research Institutes
        • Others
      • Brazil
        • Brazil Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Brazil Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Brazil Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Mexico
        • Mexico Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Mexico Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Mexico Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Argentina
        • Argentina Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Argentina Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Argentina Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
    • MEA
      • MEA Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
        • Flow Cytometry
        • Polymerase Chain Reaction (PCR)
        • Next Generation Screening (NGS)
        • Others
      • MEA Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
        • Hematological Malignancy
          • Leukemia
          • Lymphoma
        • Solid Tumors
      • MEA Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
        • Hospitals and Specialty Clinics
        • Diagnostic Laboratories
        • Academic and Research Institutes
        • Others
      • South Africa
        • South Africa Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • South Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • South Africa Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Saudi Arabia
        • Saudi Arabia Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Saudi Arabia Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Saudi Arabia Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • UAE
        • UAE Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • UAE Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • UAE Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others
      • Kuwait
        • Kuwait Minimal Residual Disease Testing Market, By Technology 2018- 2030 (USD Million)
          • Flow Cytometry
          • Polymerase Chain Reaction (PCR)
          • Next Generation Screening (NGS)
          • Others
        • Kuwait Minimal Residual Disease Testing Market, By Cancer Type, 2018- 2030 (USD Million)
          • Hematological Malignancy
            • Leukemia
            • Lymphoma
          • Solid Tumors
        • Kuwait Minimal Residual Disease Testing Market, By Business 2018- 2030 (USD Million)
          • Hospitals and Specialty Clinics
          • Diagnostic Laboratories
          • Academic and Research Institutes
          • Others

Report Content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s Five Forces analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2018 to 2030
  • Market estimates and forecast for product segments up to 2030
  • Regional market size and forecast for product segments up to 2030
  • Market estimates and forecast for application segments up to 2030
  • Regional market size and forecast for application segments up to 2030
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon